My email to Dr. Woodcock: Dr. Woodcock. I am wri

My email to Dr. Woodcock:

Dr. Woodcock.

I am writing to ask for your support for Leronlimab as a therapeutic for Covid-19

Although Leronlimab did not meet its primary endpoint of fatalities at 28 days, in a Phase 3 trial, it did show dramatic improvement in the current standard of care.

This latest trial also established, with statistical significance, that Covid patients got out of the hospital six days sooner with Leronlimab than with the SOC.

Finally, treatment in over 1,000 patients has demonstrated that Leronlimab has no toxicity, and no serious adverse events.

You previously expressed your support for any drugs that improved upon the SOC for Covid-19, regardless of P its value.

I support that pragmatic approach, while we continue to battle Covid-19, and it's variants. I would therefore urge you to support an EUA for Leronlimab, while further trials continue.

I close with this question:

If you or a loved one became infected with Covid-19, and were intubated as a result, would you not want to have the option to use a safe drug that has proven to reduce both mortality, and the length of hospitalization?

Unless you cannot honestly say no to this question, it is important that Leronlimab be made available now

Thank you,


Get BlueMail for Android

The Lawmanstyle="color:red">The Lawman"color:red">The Lawman:red">The LawmanThe Lawmanspan>Lawmanawmanimg]